Open science in clinical trials and debates about the role of research ethics committees: insights from the European Union

Open science is expected to become an integral component of clinical trials, but, in practice, it is fragmented across various guidelines, laws, funder rules, registry requirements and publishing standards. This fragmentation creates practical challenges for research ethics committees (RECs), which are responsible for protecting participants and reviewing transparency commitments often managed and enforced by other actors such as sponsors, regulators, journals and data access bodies. Focusing on the EU governance context, this multidisciplinary normative analysis examines four transparency practices – open publications, trial registration, results reporting and data sharing – and traces how each has evolved from softer ethical expectations into more institutionalized governance structures. It then analyses what these developments mean for REC review in practice. The paper argues that the mentioned developments do not impact REC work evenly: in some areas, they clarify points of REC involvement, while in others, they mainly reveal the limits of REC influence and the need for clearer responsibility boundaries.

Authors

Institutions

Publication Details

Journal
Health Research Policy and Systems
Published
2026-11-17
DOI
https://doi.org/10.1186/s12961-026-01556-4
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Open science in clinical trials and debates about the role of research ethics committees: insights from the European Union

Vygintas Aliukonis, Margarita Poškutė, Eugenijus Gefenas, Vilma Lukaševičienė
Health Research Policy and Systems
Ethics in Clinical Research
article

Open science in clinical trials and debates about the role of research ethics committees: insights from the European Union

Vygintas Aliukonis, Margarita Poškutė, Eugenijus Gefenas, Vilma Lukaševičienė
article en

Abstract

Open science is expected to become an integral component of clinical trials, but, in practice, it is fragmented across various guidelines, laws, funder rules, registry requirements and publishing standards. This fragmentation creates practical challenges for research ethics committees (RECs), which are responsible for protecting participants and reviewing transparency commitments often managed and enforced by other actors such as sponsors, regulators, journals and data access bodies. Focusing on the EU governance context, this multidisciplinary normative analysis examines four transparency practices – open publications, trial registration, results reporting and data sharing – and traces how each has evolved from softer ethical expectations into more institutionalized governance structures. It then analyses what these developments mean for REC review in practice. The paper argues that the mentioned developments do not impact REC work evenly: in some areas, they clarify points of REC involvement, while in others, they mainly reveal the limits of REC influence and the need for clearer responsibility boundaries.

Health Research Policy and Systems
Vilnius University (LT)
Peace, justice, and strong institutions
Ethics in Clinical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon